EDMONTON, ALBERTA--(Marketwire - June 23, 2010) - Ceapro Inc. (TSX VENTURE: CZO) is pleased to announce today the completion of a new marketing partnership and distribution agreement with UK firm, Oat Cosmetics Ltd. The agreement encompasses all of Ceapro's current range of all-natural active ingredients.
Oat Cosmetics is an ethical, customer-focused company supplying the market with 100% natural, traceable cosmetic ingredients. The company recently announced the global launch of its first products including Ceapro Oat avenanthramides. The company plans to extend its portfolio with the launch in a few months of other ingredients (including Ceapro Oat Beta Glucan as well as enhanced formulations of Ceapro Oat Peptides and Ceapro Sweet Blue Lupin Peptides).
Said Mr Cark Maunsell, Managing Director of Oat Cosmetics "We anticipate the combination of Ceapro's quality products and Oat Services strengths in marketing and formulation in the UK market will provide the foundation for a very successful long-term partnership."
Ceapro President and Acting CEO, Mr. Gilles Gagnon reaffirmed the Company's growth strategy of international market expansion. "We are very pleased to team up with Oat Cosmetics which has made a significant investment in marketing and formulation services in support of the launch. This is a step forward in implementing our new strategy of partnering with notable regional and market sector specialists. By positioning our new compounds in the $8 billion global market for all-natural cosmetics we fully expect to win over new customers to our products and expertise."
About Ceapro Inc.
Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of natural products for personal care and cosmetic industries using proprietary technology and natural, renewable resources. The commercial line of natural active ingredients include beta glucan, avenanthamides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides.
To learn more about Ceapro, visit www.ceapro.com
The TSX Venture Exchange nor its Regulation Services Provide (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.